BioSpace News Archive

Ancora Heart, Inc. today announced that a late-breaking clinical science presentation featuring the latest data from studies of the investigational AccuCinch ® Ventricular Restoration System will take place at the upcoming Technology and Heart Failure Therapeutics conference (THT 2023).

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET.

The Pancreatic Cancer Action Network received a $25 million gift that will accelerate the organization’s critical research initiatives to detect the disease earlier and find better treatment options for pancreatic cancer patients.

Puma Biotechnology, Inc. announced that the results of the Phase II TBCRC041 randomized clinical trial of alisertib alone or in combination with fulvestrant in patients with endocrine-resistant advanced breast cancer.

CXL Ophthalmics, Inc., a clinical-stage company developing a minimally-invasive treatment for keratoconus, announced that Tiffany Haynes has been appointed as Vice President of Clinical Operations.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare (TSX:MRV; OTCQX:MRVFF) (“Miravo” or the “Company”) and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company (“Searchlight”), are pleased to announce the closing of the previously announced plan of arrangement (the “Arrangement”) of Miravo with Searchlight.

Artisan Bio today announced an extension of its research collaboration with Takeda which leverages Artisan’s genome editing technology.

Myosin Therapeutics Inc. announced that it supplemented its National Institutes of Health funding with a seed funding round to advance the company’s lead programs on glioblastoma and stimulant use disorder.

Egg Medical, Inc. is excited to announce that Paul Pharris will be joining the Company as the Chief Revenue Officer and VP of Sales and Business Development.

Oxurion NV announced that it has enrolled more than two-thirds of the planned total enrollment in its KALAHARI Phase 2, Part B clinical trial.